Yajing Feng

Secondary prevention of cancer therapy-induced thrombocytopenia with hetrombopag in breast cancer: a multicenter, randomized, exploratory phase II trial

Abstract Background: Cancer therapy-induced thrombocytopenia (CTIT) is a common complication of anti-tumor therapy, leading to treatment delays or interruptions, increased bleeding risk and compromised outcomes. In the present study, we aimed to evaluate the efficacy and safety o...